Simultaneous Estimation of Naproxen and Ranitidine HCl by Using UV Spectrophotometer
The development of a UV Spectrophotometric method for simultaneous estimation of Ranitidine HCl and Naproxen involves absorbance measurement of Ranitidine HCl at 313 nm in pH 7.4 phosphate buffer and 314 nm in both 0.1N HCl and in water and that of Naproxen at 229 nm in pH 7.4 phosphate buffer and 232 nm in both 0.1N HCl and in water corresponding to the respective absorption maxima. Both the drugs obey Beer- Lambert's law in the range of 5-25 Î¼g/ml for Ranitidine HCl and 0.2-1.25 Î¼g/ml for Naproxen. The method developed was validated to determine its linearity, precision, reproducibility and sensitivity. The tablet formulations were evaluated for the percent content of both the drugs at the selected wavelengths and the percent potency were 98.83 and 99.15 for Naproxen and Ranitidine HCl respectively.
Key words: Naproxen, Ranitidine HCl, Ultraviolet spectroscopy, marketed products.
doi:10.3329/sjps.v1i1.1781 ÂS. J. Pharm. Sci. 1(1&2): 18-24
Each author must agree to this statement
Authorship: This manuscript is the original work of the authors, each of whom has read and approved of the work. Each author satisfied the requirements contained in 'Author Guidelines' having participated sufficiently in the work to take public responsibility for the content. This participation includes:
- Conception or design of the study, or analysis and interpretation of data, or both
- Drafting the article or revising it for critically important intellectual content
- Approval of the final 'to be published' version
All authors must take responsibility for the integrity of the work. Participating solely in the collection of data does not justify authorship.
Prior publication: This work is not currently under consideration by any other journal. Information about prior publication of any part of this work, or inclusion of patients detailed herein in any other work, has been provided in the cover letter.
Conflict of interest: Details of any financial or other relationship between any author and any other party that may lead to a conflict of interest with the subject or any materials mentioned in this article have been disclosed in the cover letter.